Trial Profile
A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacogenomic; Therapeutic Use
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Feb 2013 New trial record